The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Epidemiology of Hepatocellular Carcinoma
Open accessAbstract
Liver cancer is a major contributor to the worldwide cancer burden. Incidence rates of this disease have increased in many countries in recent decades. As the principal histologic type of liver cancer, hepatocellular carcinoma (HCC) accounts for the great majority of liver cancer diagnoses and deaths. Hepatitis B virus (HBV) and hepatitis C virus (HCV) remain, at present, the most important global risk factors for HCC, but their importance will likely decline in the coming years. The effect of HBV vaccination of newborns, already seen in young adults in some countries, will be more notable as vaccinated cohorts age. In addition, effective treatments for chronic infections with both HBV and HCV should contribute to declines in the rates of viral‐associated HCC. Unfortunately, the prevalence of metabolic risk factors for HCC, including metabolic syndrome, obesity, type II diabetes and non‐alcoholic fatty liver disease (NAFLD) are increasing and may jointly become the major cause of HCC globally. Excessive alcohol consumption also remains an intractable risk factor, as does aflatoxin contamination of food crops in some parts of the world. While significant efforts in early diagnosis and better treatment are certainly needed for HCC, primary prevention efforts aimed at decreasing the prevalence of obesity and diabetes and controlling mycotoxin growth, are just as urgently required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018) · Hepatology · doi:10.1002/hep.29913 · Cited by 4,539
Body Fatness and Cancer — Viewpoint of the IARC Working Group
Lauby-Secretan, B., Scoccianti, C., Loomis, D., Grosse, Y., Bianchini, F., & Straif, K. (2016) · New England Journal of Medicine · doi:10.1056/nejmsr1606602 · Cited by 3,596
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
El-Serag, H. B. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.061 · Cited by 3,380
Self-citationVernon, G., Baranova, A., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,074
Alcohol consumption and site-specific cancer risk: a comprehensive dose–response meta-analysis
Bagnardi, V, Rota, M., Botteri, E., Tramacere, I., Islami, F., Fedirko, V, Scotti, L., Jenab, M., Turati, F., Pasquali, E., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.579 · Cited by 1,342
Frezza, M., di Padova, C., Pozzato, G., Terpin, M., Baraona, E., & Lieber, C. S. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001113220205 · Cited by 1,328
Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma
El-serag, H. B., Tran, T., & Everhart, J. E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.10.065 · Cited by 1,230
Self-citationContemporary Epidemiology of Chronic Liver Disease and Cirrhosis
Moon, A. M., Singal, A. G., & Tapper, E. B. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.07.060 · Cited by 1,150
Cited by
Global burden of primary liver cancer in 2020 and predictions to 2040
Rumgay, H., Arnold, M., Ferlay, J., Lesi, O., Cabasag, C. J., Vignat, J., Laversanne, M., McGlynn, K. A., & Soerjomataram, I. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.08.021 · Cited by 2,197
Self-citationAASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052
Yeo, Y. H., Samaan, J. S., Ng, W. H., Ting, P.-S., Trivedi, H., Vipani, A., Ayoub, W., Yang, J. D., Liran, O., Spiegel, B., et al. (2023) · doi:10.1101/2023.02.06.23285449 · Cited by 666
Yeo, Y. H., Samaan, J. S., Ng, W. H., Ting, P.-S., Trivedi, H., Vipani, A., Ayoub, W., Yang, J. D., Liran, O., Spiegel, B., et al. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0089 · Cited by 662
Is early-onset cancer an emerging global epidemic? Current evidence and future implications
Ugai, T., Sasamoto, N., Lee, H.-Y., Ando, M., Song, M., Tamimi, R. M., Kawachi, I., Campbell, P. T., Giovannucci, E. L., Weiderpass, E., et al. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00672-8 · Cited by 603
Global Epidemiology and Genetics of Hepatocellular Carcinoma
Toh, M. R., Wong, E. Y. T., Wong, S. H., Ng, A. W. T., Loo, L.-H., Chow, P. K.-H., & Ngeow, J. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.01.033 · Cited by 583
Ganesan, P., & Kulik, L. M. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.08.004 · Cited by 478
Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers
Wang, Y., & Deng, B. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10084-4 · Cited by 415
Changing epidemiology of hepatocellular carcinoma in Asia
Zhang, C., Cheng, Y., Zhang, S., Fan, J., & Gao, Q. (2022) · Liver International · doi:10.1111/liv.15251 · Cited by 335
Matrix viscoelasticity promotes liver cancer progression in the pre-cirrhotic liver
Fan, W., Adebowale, K., Váncza, L., Li, Y., Rabbi, M. F., Kunimoto, K., Chen, D., Mozes, G., Chiu, D. K.-C., Li, Y., et al. (2024) · Nature · doi:10.1038/s41586-023-06991-9 · Cited by 263
LeFort, K. R., Rungratanawanich, W., & Song, B.-J. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05061-7 · Cited by 202
Psaraki, A., Ntari, L., Karakostas, C., Korrou‐Karava, D., & Roubelakis, M. G. (2022) · Hepatology · doi:10.1002/hep.32129 · Cited by 145
Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg
Fernández-Barrena, M. G., Arechederra, M., Colyn, L., Berasain, C., & Avila, M. A. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100167 · Cited by 126
Yau, T., Kaseb, A., Cheng, A.-L., Qin, S., Zhu, A. X., Chan, S. L., Melkadze, T., Sukeepaisarnjaroen, W., Breder, V., Verset, G., et al. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00454-5 · Cited by 97
Rational HCC screening approaches for patients with NAFLD
Singal, A. G., & El-Serag, H. B. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.08.028 · Cited by 80
Self-citationMASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women
Milani, I., Chinucci, M., Leonetti, F., & Capoccia, D. (2025) · Biomedicines · doi:10.3390/biomedicines13040855 · Cited by 38
“In liver cancer, MASH has surpassed alcohol-related liver disease as the leading cause of HCC [42], with men generally experiencing rates two to four times higher than women [44,45].”
Rusu, I., Pirlog, R., Chiroi, P., Nutu, A., Puia, V. R., Fetti, A. C., Rusu, D. R., Berindan-Neagoe, I., & Al Hajjar, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012370 · Cited by 27
Xia, P., Liu, D.-H., Wang, D., Wen, G.-M., & Zhao, Z.-Y. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.07.002 · Cited by 14
Nerusch, J., Schicht, G., Herzog, N., Küpper, J.-H., Seehofer, D., & Damm, G. (2025) · Cells · doi:10.3390/cells14161254 · Cited by 3
Metadata
- Authors
- McGlynn, K. A., Petrick, J. L., & El‐Serag, H. B.
- Venue
- Hepatology
- Published
- 2020-11-24
- Volume
- 73
- Issue
- S1
- Pages
- 4-13
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W3021610682
- Cited by
- 2,147
- References
- 86
- FWCI
- 135.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.